Olympus Slashes FY2026 Profit Outlook on Surgical Shipment Disruptions

The latest announcement is out from Olympus ( (JP:7733) ).

Olympus has sharply revised down its earnings forecast for the fiscal year ending March 31, 2026, while keeping revenue guidance unchanged at ¥998 billion, underscoring mounting pressure on profitability despite stable top-line expectations. The company now expects operating profit to fall by 36.0% to 44.9% versus its prior outlook, with profit attributable to owners of the parent cut by up to roughly 47%, reflecting a deterioration from the previous year’s performance.

Management cited weaker-than-expected progress in the third quarter and shipment suspensions in the Surgical & Interventional Solutions Division as key reasons for the downgrade, and introduced forecast ranges to account for heightened uncertainty. The revisions, which mark a significant step down from both the earlier guidance and the prior year’s results, signal operational headwinds in core businesses and could weigh on investor sentiment as Olympus navigates a more challenging operating and competitive environment.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2140.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

More about Olympus

Olympus Corporation is a Japan-based medical technology company listed on the Tokyo Stock Exchange that focuses on endoscopic, surgical, and interventional solutions. The group has been streamlining its portfolio, including classifying its Orthopedic Business as a discontinued operation from fiscal 2025, to concentrate on core healthcare segments and improve profitability over the long term.

Average Trading Volume: 3,099,279

Technical Sentiment Signal: Hold

Current Market Cap: Yen2174.2B

Learn more about 7733 stock on TipRanks’ Stock Analysis page.